REPL · Replimune Group, Inc.
$5.35
-3.28 (-38.01%)
At close · Jul 28
Going-concern doubt
— flagged Jun 29, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-K filed Jun 29, 2026
Market Cap
$449.11M
Shares
83.95M
Replimune Group, Inc. Earnings Call Transcripts
Every quarterly earnings call for Replimune Group, Inc. (REPL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY25 · Q4
2025-05-22
Replimune Group, Inc. Q4 FY2025 Earnings Call
Confident tone
RP1 regulatory progress and PDUFA
Anti-PD-1 failed melanoma market opportunity
RP1 commercial launch preparation
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2023-11-07
Replimune Group, Inc. Q2 FY2024 Earnings Call
Diluted EPS
$-0.90
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q3
2020-01-15
Replimune Group, Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–3 of 3 earnings calls
Key facts
CIK
1737953
CUSIP
76029N106
13F (30d)
36 filings
36 filers
Visit website
Investor relations